Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)

Luke, David R.; Tomaszewski, Konrad E.; Damle, Bharat; Schlamm, Haran T.

doi:10.1002/jps.22109

Cited by 194 publications

(181 citation statements)

References 21 publications

Supporting

Mentioning

170

Contrasting

Order By: Relevance

“…ministered with twice-daily voriconazole (approximately 84 mg/kg of body weight per day for an 80-kg patient versus 128 mg/kg/day, respectively). The half-life of SBECD was still prolonged, at 12.9 h, compared to the half-life of 1.6 to 2 h observed in healthy volunteers with normal renal function (6). This is consistent with our knowledge that SBECD is highly correlated with CL CR (r 2 ϭ 0.857) (8).…”

Section: Figsupporting

confidence: 90%

See 1 more Smart Citation

Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration

Morris

Mueller

Rower

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

cWe present a 31-year-old female who had undergone an allogeneic bone marrow transplantation and who was started on intravenous posaconazole for pulmonary mycosis while undergoing continuous venovenous hemofiltration (CVVH). We performed steady-state pharmacokinetic evaluations for both posaconazole and sulfobutylether-␤-cyclodextrin (SBECD). SBECD was effectively removed by CVVH, with observed exposure similar to that for patients with moderate renal impairment. Intravenous posaconazole at standard doses may be utilized in critically ill patients undergoing CVVH without significant risk of SBECD accumulation.

show abstract

Section: Figsupporting

confidence: 90%

“…It is recommended that i.v. posaconazole be avoided in patients with a creatinine clearance (CL CR ) of less than 50 ml/min/ 1.73 m 2 to prevent accumulation of SBECD, which may be associated with hepatotoxicity and nephrotoxicity (1,6).…”

mentioning

confidence: 99%

Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration

Morris

Mueller

Rower

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The oral formulations have exhibited significant inter-patient and intra-patient variations in bioavailability due to inconsistent absorption, metabolism, elimination, or drug-drug interactions. The intravenous formulation is suitable for patients who cannot tolerate oral formulation, however, its solubilizing excipient may cause additional renal toxicity for patients with renal impairment [12]. Posaconazole could accumulate in tissues due to its hydrophobic nature; as such, its disposition could perhaps augment its efficacy.…”

Section: Introductionmentioning

confidence: 99%

Determination of Posaconazole in Plasma/Serum by High-Performance Liquid Chromatography with Fluorescence Detection

Tang

2017

Separations

View full text Add to dashboard Cite

Abstract:A sensitive high-performance liquid chromatographic (HPLC) method is described for the determination of posaconazole in human plasma/serum. The method is based on a single dilution step by treating the sample with methanol, and followed by the direct injection of the sample into the HPLC system. Posaconazole and internal standard ketoconazole in the methanol extract are subsequently analyzed by using a fluorescence (FL) detector at optimized wavelengths (excitation 245 nm and emission 380 nm). The method achieves a linear detector response for peak height measurements over the concentration range of 0.1-10 µg/mL which adequately covers the therapeutic range for appropriate patient monitoring. The chromatographic time is less than 8 min per injection, an improvement over most published HPLC/FL or HPLC/UV methods. The method's limit of quantitation, linearity, imprecision, and accuracy met all criteria required by the Guidance for Industry Bioanalytical Method Validation. In comparison to other published methods, the current method would be of interest to analytical and clinical laboratories because it employs simple, rapid, and cost-effective procedures.

show abstract

“…To find the suitable conditions for the chiral separation of the model molecules, a series of preliminary experiments were conducted with different buffer compositions at different pH values, in order to characterize the electrophoretic behavior of the analytes in an achiral system over a wide adjustable pH range (2)(3)(4)(5)(6)(7)(8)(9)(10)(11). In the preliminary analysis we used: 25 mM phosphoric acid (pH -2.1), 25 mM sodium didydrogenophosphate (pH -5.0), 25 mM disodium hydrogenophosphate -sodium didydrogenophosphate (1:1) (pH -7.0) and 25 mM sodium tetraborate (pH -9.3) BGEs respectively and we modified the pH of the buffer by adding a 0.1M sodium hydroxide solution.…”

Section: Resultsmentioning

confidence: 99%

Captisol® as Chiral Selector in Capillary Electrophoresis of Non-Acidic Drugs

Budău

Hancu

Szabó

et al. 2017

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

Enantioseparation of nine extensively used chiral pharmaceutical substances from different pharmacological classes and with different structural characteristics has been investigated by capillary zone electrophoresis using Captisol® (sulfobuthylether-β-cyclodextrin sodium salt) as chiral selector. The influence on the chiral separation of several parameters including pH and concentration of the background electrolyte, chiral selector concentration, applied voltage, system temperature and injection parameters were studied and optimized in order to obtain increased chiral resolution and shorten analysis time. The results were compared with those obtained with native and derivatized neutral cyclodextrins (β-cyclodextrin and hydroxypropryl-β-cyclodextrin). All model molecules were resolved using Captisol® as chiral additive and optimized electrophoretic conditions, proving the efficiency of this anionic derivative of β-cyclodextrin as chiral selector in capillary electrophoresis.

show abstract

Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)

Cited by 194 publications

References 21 publications

Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration

Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration

Determination of Posaconazole in Plasma/Serum by High-Performance Liquid Chromatography with Fluorescence Detection

Captisol® as Chiral Selector in Capillary Electrophoresis of Non-Acidic Drugs

Contact Info

Product

Resources

About